Data of a prospective cohort suggest that chronic systemic low-grade inflammation, as measured by CRP, plays a role in development of cancer, particularly of the lung, in those with stable CVD.
During the last 30 years, clinical characteristics of HF patients have changed; nowadays, obesity is common in HF. Dr. Packer explains why obesity plays such an important role in HFpEF.
A single-center prospective PCI-registry showed an independent association of high residual inflammatory risk and adverse clinical outcomes in patients undergoing PCI with LDL-c ≤70 mg/dL at baseline.
EAS 2019 Paul Ridker discusses the positive effect of canakinumab on, in particular, non-small cell lung cancer incidence and mortality, as demonstrated in the CANTOS trial.
Bleeding on probing, increased probing pocket depth, caries or fillings in childhood were associated with increased IMT 27 years later, independent of cumulative exposure to CV risk factors.
This observational study showed prognostic value of IL-1β for acutely decompensated HF (ADHF) in those with high sST2 (IL-1 receptor) levels, and a meaningful correlation between IL-1β and sST2.
In a secondary analysis of the VISTA-16 trial, hsCRP levels measured at the time of ACS and increases of hsCRP in the 16 weeks after, were correlated with MACE, all-cause and CV death.
Large population-based study with 10 years follow-up showed that frequent tooth brushing and regular dental visits lower the risk of CV events associated with oral health problems.
In the ANITSCHKOW study, 16 weeks of treatment with evolocumab in patients with elevated Lp(a) levels, did not significantly alter arterial wall inflammation, despite lowering Lp(a) by 14%.
AHA 2018 In the ANITSCHKOW study, patients with very high Lp(a) were treated with evolocumab 420 mg once monthly. The 14% lowering in Lp(a) was not sufficient to eliminate the inflammatory stimulans induced by Lp(a).
Patients with HF with LVEF >40% showed greater total epicardial fat content, which was not related to BMI. Epicardial fat volume was associated with the presence of AF and T2DM.
AHA 2018 Paul Ridker outlines how the new CIRT results add to our understanding of inflammation biology in relation to CV risk and how this directs future studies of inflammation.